CRME

Ls 2x Salesforc (CRME)

Ls 2x Salesforc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:CRME

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/04/24	23 : 47	UK Regulatory	Leverage Shares PLC Issuer Call Redemption Confirmation	LSE:CRME	Ls 2x Salesforc
2009/12/22	07 : 05	PR Newswire (US)	Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans	LSE:CRME
2009/12/18	08 : 00	PR Newswire (US)	Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study	LSE:CRME
2009/11/09	22 : 40	PR Newswire (US)	Cardiome Reports Third Quarter Results	LSE:CRME
2009/11/07	08 : 00	PR Newswire (US)	Cardiome to Release Third Quarter Results	LSE:CRME
2009/11/03	04 : 35	PR Newswire (US)	Cardiome To Present At Oppenheimer Healthcare Conference	LSE:CRME
2009/10/29	05 : 58	PR Newswire (US)	Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial	LSE:CRME
2009/10/17	09 : 54	PR Newswire (US)	Cardiome Pharma Corp. Announces Final Results of Tender Offer	LSE:CRME
2009/10/14	19 : 00	PR Newswire (US)	Cardiome Pharma Corp. Announces Preliminary Results of Tender Offer	LSE:CRME
2009/09/02	03 : 57	PR Newswire (US)	Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer	LSE:CRME
2009/08/29	02 : 30	PR Newswire (US)	Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of	LSE:CRME
2009/08/26	06 : 11	PR Newswire (US)	Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares	LSE:CRME
2009/08/11	20 : 45	PR Newswire (US)	Cardiome Reports Second Quarter Results	LSE:CRME
2009/08/11	08 : 45	PR Newswire (US)	Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement	LSE:CRME
2009/08/11	05 : 35	PR Newswire (US)	Cardiome to Hold Conference Call	LSE:CRME
2009/08/04	06 : 16	PR Newswire (US)	Cardiome Announces Management Transition	LSE:CRME
2009/07/29	00 : 45	PR Newswire (US)	Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.	LSE:CRME
2009/05/19	21 : 30	PR Newswire (US)	Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective	LSE:CRME
2009/05/16	05 : 05	PR Newswire (US)	Cardiome Reports First Quarter Results	LSE:CRME
2009/04/09	07 : 13	PR Newswire (US)	Cardiome to Hold Conference Call	LSE:CRME
2008/11/29	07 : 31	PR Newswire (US)	Cardiome Discloses Chairman And CEO's Involuntary Share Sale	LSE:CRME
2008/11/15	08 : 40	PR Newswire (US)	Cardiome Reports Third Quarter Results	LSE:CRME
2008/10/24	11 : 40	PR Newswire (US)	Cardiome Announces Filing Of Shelf Registration Statement	LSE:CRME
2008/10/10	01 : 20	PR Newswire (US)	Cardiome Provides Regulatory Update	LSE:CRME
2008/08/13	05 : 05	PR Newswire (US)	Cardiome Reports Second Quarter Results	LSE:CRME
2008/08/12	05 : 30	PR Newswire (US)	Cardiome to Release Second Quarter Results and Hold Conference Call	LSE:CRME
2008/08/11	22 : 18	PR Newswire (US)	Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)	LSE:CRME
2008/07/24	03 : 10	PR Newswire (US)	Cardiome Announces Preferred Share Financing	LSE:CRME
2008/07/14	21 : 25	PR Newswire (US)	Cardiome Announces Positive Phase 2b Results For Oral Vernakalant	LSE:CRME
2008/07/14	01 : 00	PR Newswire (US)	Cardiome To Hold Conference Call	LSE:CRME